Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27689197 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| SCHEMBL7175620 | 0.88 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| SCHEMBL2172151 | 0.86 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| Hydrochloric Acid SCHEMBL19809919 | 0.86 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| SCHEMBL20260781 | 0.85 | AOC3 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| SCHEMBL9563665 | 0.84 | AOC3 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| SCHEMBL1006488 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| SCHEMBL10614871 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| Hydrochloric Acid SCHEMBL7709817 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 | |
| SCHEMBL176479 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109535482-A | A kind of no resin, nano flame retardant masterbatch of binder free and preparation method thereof | 大连亚泰科技新材料股份有限公司 | 2019-03-29 | — | — | CN | claimed |
| CN-101210305-B | Tungsten alloy composite plating coat material and manufacturing method thereof | WEI WANG | 2011-09-28 | — | — | CN | claimed |
| CN-101210305-A | Tungsten alloy composite plating coat material and manufacturing method thereof | WEI WANG (CN) | 2008-07-02 | — | — | CN | claimed |
| CN-1323459-C | Fuel battery structure and process for preparing same | UNIV TIANJIN (CN) | 2007-06-27 | — | — | CN | claimed |
| CN-1667860-A | Fuel battery structure and process for preparing same | UNIV TIANJIN (CN) | 2005-09-14 | — | — | CN | claimed |
| CN-109535482-A | A kind of no resin, nano flame retardant masterbatch of binder free and preparation method thereof | 大连亚泰科技新材料股份有限公司 | 2019-03-29 | — | — | CN | disclosed |
| US-9365552-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| CN-103014819-A | Wearable compound layer material for machine parts and manufacturing method and equipment thereof | XIAO YUNJIE | 2013-04-03 | — | — | CN | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| CN-101210305-B | Tungsten alloy composite plating coat material and manufacturing method thereof | WEI WANG | 2011-09-28 | — | — | CN | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| CN-101210305-A | Tungsten alloy composite plating coat material and manufacturing method thereof | WEI WANG (CN) | 2008-07-02 | — | — | CN | disclosed |
| CN-100348780-C | Method of pulse plating nickel based nano composite plating layer and equipment | UNIV TIANJIN (CN) | 2007-11-14 | — | — | CN | disclosed |
| CN-1323459-C | Fuel battery structure and process for preparing same | UNIV TIANJIN (CN) | 2007-06-27 | — | — | CN | disclosed |
| CN-1924112-A | Composite plating coat material for metallurgy conticaster crystallizer, preparation method and apparatus thereof | UNIV TIANJIN (CN) | 2007-03-07 | — | — | CN | disclosed |
| CN-1667860-A | Fuel battery structure and process for preparing same | UNIV TIANJIN (CN) | 2005-09-14 | — | — | CN | disclosed |
| CN-1563505-A | Method of pulse plating nickel based nano composite plating layer and equipment | UNIV TIANJIN (CN) | 2005-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CHRNB2 280/4885CHRNB4 231/4885CHRNA3 197/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CHRNB2 280/4885CHRNB4 231/4885CHRNA3 197/4885 |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CHRNB2 280/4885CHRNB4 231/4885CHRNA3 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.